|
Neoplasms
|
0.080 |
Biomarker
|
group |
BEFREE |
In addition, anti-HER2/neu IgG3-(GM-CSF) was able to target the HER2/neu-expressing murine tumor CT26-HER2/neu and enhance the immune response against the targeted Ag HER2/neu.
|
11046042 |
2000 |
|
Lupus Erythematosus, Systemic
|
0.060 |
Biomarker
|
disease |
BEFREE |
In addition, the roles of IgG4-IgG1 (IgG4-IgG2 or IgG4-IgG3)-complexes and bispecific IgG4 in SLE and RA are also reviewed.
|
28472610 |
2017 |
|
Clinical malaria
|
0.060 |
Biomarker
|
disease |
BEFREE |
This study examines the hypotheses that the IgG3-H435 variant promotes increased transplacental transfer of malaria-specific antibodies and a prolonged IgG3 half-life in infants and that its presence correlates with protection against clinical malaria during infancy.
|
28991911 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.060 |
Biomarker
|
disease |
BEFREE |
Patients with low IgG3 or IgG4 presented higher frequency of lupus nephropathy.
|
27274095 |
2016 |
|
Clinical malaria
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
High levels of antibodies, particularly IgG3, were strongly predictive of protection against clinical malaria and high-density parasitemia.
|
23028883 |
2012 |
|
Lupus Erythematosus, Systemic
|
0.060 |
Biomarker
|
disease |
BEFREE |
To clarify the role played by Fkn in the development of glomerular lesions in lupus nephritis, we examined Fkn expression and CD16(+) Mo accumulation induced in experimental C.B-17/Inc-scid/scid (SCID) lupus model mice by injection of IgG(3)-producing hybridoma clones obtained from MRL/lpr mice.
|
20410215 |
2010 |
|
Clinical malaria
|
0.060 |
Biomarker
|
disease |
BEFREE |
We determined whether this protection was allele-specific by testing whether children who developed clinical malaria lacked IgG/IgG3 antibodies specific to the dominant msp2 parasite genotypes detected during clinical episodes.
|
20398182 |
2010 |
|
Clinical malaria
|
0.060 |
Biomarker
|
disease |
BEFREE |
Our results also revealed that the natural acquisition of immunity against clinical malaria appeared to be more associated with IgG1 and IgG3 antibodies, signifying their roles in parasite-neutralizing immune mechanisms.
|
17587350 |
2007 |
|
Lupus Erythematosus, Systemic
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
The Fc gamma RIIIA-V/F158 polymorphism affects immunoglobulins (Ig)G1- and IgG3-binding capacity and may modulate the expression of renal disease in patients with systemic lupus erythematosus (SLE).
|
12631364 |
2003 |
|
Clinical malaria
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
After adjusting for potentially confounding effects of age and pre-season parasitaemia, IgG3 reactivities against each of the major serogroups of MSP2 remained significantly associated with a lower prospective risk of clinical malaria.
|
14507328 |
2003 |
|
Lupus Erythematosus, Systemic
|
0.060 |
Biomarker
|
disease |
BEFREE |
The role of the Yaa gene for the acceleration of SLE is apparently two-fold; it enhances overall autoimmune responses against autoantigens to which mice respond relatively weakly, and promotes Th 1 responses against autoantigens to which mice respond relatively well, leading to the production of more pathogenic autoantibodies, i.e., FcgammaR-fixing IgG2a and cryoglobulin IgG3 autoantibodies.
|
11016427 |
2000 |
|
Clinical malaria
|
0.060 |
Biomarker
|
disease |
BEFREE |
In a large population study in The Gambia, serum positivity for IgG or IgG1 and IgG3 subclass antibodies to each of the EBA-175 recombinant antigens was not significantly associated with subsequent protection from clinical malaria.
|
10992454 |
2000 |
|
Lupus Erythematosus, Systemic
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
We demonstrate herein that the accelerated development of lupus-like autoimmune disease in MRL-lpr/lpr and MRL.Yaa mice, as compared with MRL-lpr/lpr.ll and MRL-+/+ mice, respectively, was correlated with an enhanced expression of IFN-gamma vs IL-4 and IL-10 mRNA in CD4+ T cells, which paralleled with an increase of spontaneous and foreign T cell-dependent antigen-induced productions of IgG2a and IgG3 vs IgG1 antibodies.
|
8601623 |
1996 |
|
Rheumatoid Arthritis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
IgG3 levels were significantly higher in HCV-MC patients with a decrement of IgG2 and IgG4; FLC levels significantly increased in both MC and RA patients' groups; serological VEGF was higher in HCV-MC patients than in HBD in correlation with k and λ levels.
|
31669506 |
2020 |
|
Rheumatoid Arthritis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Rheumatoid arthritis (RA) was associated with both an isolated elevation in IgG1 and IgG3.
|
28457528 |
2017 |
|
Rheumatoid Arthritis
|
0.050 |
Biomarker
|
disease |
BEFREE |
In addition, the roles of IgG4-IgG1 (IgG4-IgG2 or IgG4-IgG3)-complexes and bispecific IgG4 in SLE and RA are also reviewed.
|
28472610 |
2017 |
|
Rheumatoid Arthritis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Three HID-RFs bound IgG3 compared with 9 RA-RFs (p = 0.007).
|
9498795 |
1998 |
|
Rheumatoid Arthritis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Clonal analysis of immunoglobulin mRNA in rheumatoid arthritis synovium: characterization of expanded IgG3 populations.
|
9045920 |
1997 |
|
HIV-1 infection
|
0.040 |
Biomarker
|
disease |
BEFREE |
We review recent studies that describe mechanisms of B-cell dysregulation in chronic HIV-1 infection associated with IgG3 and T-bet.
|
30973418 |
2019 |
|
HIV-1 infection
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
HIV-1-specific IgG3 antibodies have been correlated with decreased risk of HIV-1 infection in the RV144 trial, which included a CNPV-based vector (Yates et al.(Sci Transl Med, 6(228) p228, 2014).
|
26153454 |
2015 |
|
HIV-1 infection
|
0.040 |
Biomarker
|
disease |
BEFREE |
Env-specific IgG and IgG3 Abs, IgG avidity, and neutralizing Abs inversely correlated with CRF01_AE 169K HIV-1 infection risk in the CT- or TT-carrying vaccine recipients only.
|
25105367 |
2014 |
|
HIV-1 infection
|
0.040 |
Biomarker
|
disease |
BEFREE |
RANTES.her2.IgG3 bound specifically to the CCR5 chemokine receptor, as demonstrated by flow cytometry, and inhibited HIV-1 infection via the CCR5 coreceptor.
|
9759898 |
1998 |
|
Hepatitis C
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
IgG3 levels were significantly higher in HCV-MC patients with a decrement of IgG2 and IgG4; FLC levels significantly increased in both MC and RA patients' groups; serological VEGF was higher in HCV-MC patients than in HBD in correlation with k and λ levels.
|
31669506 |
2020 |
|
Malignant Neoplasms
|
0.030 |
GeneticVariation
|
group |
BEFREE |
In this manuscript, we have conjugated the murine IgG3-Fc with a MUC1-containing cancer vaccine and compared the humoral and cellular immune response to this vaccine with one targeted via the human anti-Rha antibody and to the MUC1 vaccine alone.
|
30949616 |
2019 |
|
Primary malignant neoplasm
|
0.030 |
GeneticVariation
|
group |
BEFREE |
In this manuscript, we have conjugated the murine IgG3-Fc with a MUC1-containing cancer vaccine and compared the humoral and cellular immune response to this vaccine with one targeted via the human anti-Rha antibody and to the MUC1 vaccine alone.
|
30949616 |
2019 |